ClinicalTrials.gg
CompletedNCT03332173Updated Oct 26, 2024Results posted

Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)

A Phase 2 interventional study of Zanubrutinib in Waldenström's Macroglobulinemia (WM), sponsored by BeiGene. Completed at 10 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by BeiGene · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Waldenstrom Macroglobulinemia by BeOne Medicines — 3 open to participants now, 5 under way, none of them phase 3. Waldenstrom Macroglobulinemia · BeOne Medicines.

Started
2017
with 1 other
Phase 2
3 of 10
none open now
Registered
2nd of 10
by date

Among the 10 studies in Waldenstrom Macroglobulinemia by BeOne Medicines, this one is one of 2 that started in 2017, is one of 3 in phase 2, and was the 2nd registered.

Waldenstrom Macroglobulinemia

524 studies on the registry are indexed under Waldenstrom Macroglobulinemia; 61 are open to participants now.

Browse Waldenstrom Macroglobulinemia studies →

Open to participants now

3 of the 10 studies in Waldenstrom Macroglobulinemia by BeOne Medicines are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 47 Waldenstrom Macroglobulinemia studies recruiting now, 43 (91%) set no upper age limit and 1 (2%) stops at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Waldenstrom Macroglobulinemia by BeOne Medicines, or all of them as a file.
02

Study summary

This was a single-arm, multicenter Phase 2 study in Chinese participants with relapsed or refractory Waldenström's macroglobulinemia who exhibited one or more of the criteria for requiring treatment based on consensus guidelines from the Seventh International Workshop on Waldenström's Macroglobulinemia (IWWM). The study comprised an initial screening phase (up to 28 days), a single-arm treatment phase, and a follow-up phase.

03

Conditions studied

  • Waldenström's Macroglobulinemia (WM)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Clinical and definitive histologic diagnosis of WM, meeting at least one criterion for treatment according to consensus panel criteria from the Seventh IWWM.
  2. WM pathology confirmation by central lab prior to study enrollment. Previous pathology report, concurrently with newly generated central lab report to be reviewed to support WM diagnosis.
  3. Men and women ≥ 18 years of age.
  4. (ECOG) performance status of 0-2.
  5. Previously treated with a minimum of 1 prior line of standard chemotherapy-containing regimen (with completion of ≥ 2 continuous treatment cycles).
  6. Documented failure to achieve at least minor response or documented disease progression after response to the most recent treatment regimen.
  7. Neutrophils ≥ 0.75 x 10\^9/L independent of growth factor support within 7 days of first dose.
  8. ≥ 50 x 10\^9/L, independent of growth factor support or transfusion within 7 days of first dose.
  9. ≥80 g/L, independent of erythropoietin (EPO) support or transfusion within 7 days of first dose of study drug.
  10. of ≥ 30 mL/min (as estimated by the Cockcroft-Gault equation or estimated [eGFR] from the Modification of Diet in Renal Disease [MDRD]).
  11. (AST) and alanine aminotransferase (ALT) ≤ 3.0 x (ULN).
  12. ≤ 2 x ULN (unless documented Gilbert's syndrome).
  13. ≤ 1.5 and activated partial thromboplastin time ≤ 1.5 x ULN. Participants with lupus anticoagulant or acquired von Willebrand disease due to WM may be enrolled after discussion with the medical monitor.
  14. ECHO must demonstrate (LVEF) ≥50%.
  15. Participants who relapse after stem cell transplant may be enrolled if they are at least 6 months after transplant at screening. To be eligible after transplant, participants should have no active related infections.
  16. Females of must agree to use highly effective forms of throughout the course of the study and at least up to 90 days after last dose of study drug. Highly effective forms of birth control can be defined as abstinence, hysterectomy, bilateral oophorectomy with no menstrual bleeding for up to 6 months, intrauterine contraception, hormonal methods such as contraceptive injection, oral contraceptive, etc. Males must have undergone sterilization-vasectomy, or use a barrier method where the female partner uses the effective forms of birth control noted above and must not donate sperm for at least 90 days after last dose of study drug.
  17. of > 4 months.
  18. Able to provide written and can understand and comply with the requirements of the study.

Key Exclusion Criteria:

  1. Central nervous system (CNS) involvement by WM.
  2. Prior exposure to a BTK inhibitor.
  3. Evidence of disease transformation.
  4. Prior given in excess of prednisone 10 mg/day or its equivalent with antineoplastic intent within 7 days, prior chemotherapy, targeted therapy, or radiation therapy within 3 weeks, antineoplastic therapy with Chinese herbal medicine or antibody based therapies within 4 weeks of the start of study drug.
  5. Major surgery within 4 weeks of randomization.
  6. Toxicity of ≥ Grade 1 from prior anti-cancer therapy (except for [ANC], platelets, and hemoglobin. For ANC, platelets, and hemoglobin, please follow inclusion criteria #7 [neutrophils], #8 [platelets], and #9 [hemoglobin]).
  7. History of other active within 2 years of study entry, with exception of (1) adequately treated in-situ carcinoma of cervix; (2) localized basal cell or squamous cell carcinoma of skin; (3) previous malignancy confined and treated locally (surgery or other modality) with curative intent.
  8. Currently active cardiovascular disease such as uncontrolled arrhythmia, uncontrolled hypertension, congestive heart failure, any Class 3 or 4 cardiac disease as defined by the (NYHA) Functional Classification, or history of myocardial infarction within 6 months of screening.
  9. prolongation (defined as a QTc >480 msecs based on Fridericia's formula) or other significant abnormalities including second degree atrioventricular (AV) block Type II, or third degree AV block.
  10. Unable to swallow capsules or disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.
  11. Active infection including infections requiring oral or intravenous anti-microbial therapy.
  12. Known (HIV), or active or infection (detected positive by polymerase chain reaction [PCR]).
  13. Pregnant or lactating women.
  14. Any life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, or put the study at risk.
  15. On medications which are strong inhibitors or strong CYP3A inducers.
  16. History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
  17. Has received allogenic hematopoietic stem cell transplantation prior to enrollment.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Zanubrutinib

    Zanubrutinib 160 mg orally twice daily with or without food until progressive disease or intolerable toxicity

    Drug: Zanubrutinib

Interventions

  • Oral administration using 80 mg capsules

    Also known as: BGB-3111, Brukinsa

06

What researchers measure

Primary outcomes

  1. Major Response Rate (MRR) as Assessed by the Independent Review Committee

    MRR is defined as the percentage of participants who achieved complete response (CR) + very good partial response (VGPR) + partial response (PR), as assessed by an independent review committee according to modified Owen's criteria

    Time frame: Up to approximately 1 year and 9 months

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by an independent review committee using modified Owen's criteria

    Time frame: Up to approximately 1 year and 9 months

  2. PFS: Event-free Rate

    Progression/death event-free rates were estimated by Kaplan-Meier method with 95% confidence intervals (CIs) estimated using Greenwood's formula

    Time frame: Up to approximately 1 year and 9 months

  3. Overall Response Rate (ORR)

    ORR is defined as the percentage of participants with a minor, partial, very good partial, and complete response, as assessed by an independent review committee using modified Owen's criteria

    Time frame: Up to approximately 1 year and 9 months

  4. Duration of Major Response (DOMR)

    DOMR is defined as the time from the date that the major response criteria are first met to the date that progressive disease (PD) is objectively documented or death, whichever comes first, as assessed by an independent review committee using modified Owen's criteria

    Time frame: Up to approximately 1 year and 9 months

  5. DOMR: Event-free Rate

    DOMR event-free rates were estimated by Kaplan-Meier method with 95% CIs estimated using Greenwood's formula

    Time frame: Up to approximately 1 year and 9 months

  6. Number of Participants With Resolution of Treatment-precipitating Symptoms

    Number of participants with resolution of treatment-precipitating symptoms, defined as any resolution (from "Yes" at baseline to "No" at any postbaseline point onwards during study) of the indications for initiation of therapy in WM signs and symptoms evaluation.

    Time frame: Up to approximately 1 year and 9 months

  7. Number of Participants With an Anti-lymphoma Effect

    Number of participants with an anti-lymphoma effect, defined as any reduction during the course of study in bone marrow involvement by lymphoplasmacytoid lymphocytes and/or size of lymphadenopathy and/or splenomegaly by computed tomography scan as assessed by an independent review committee; lymphadenopathy is defined as any node with longest diameter (LDi) \> 1.5 cm and splenomegaly is defined as vertical spleen length \> 13 cm

    Time frame: Up to approximately 1 year and 9 months

  8. Number of Participants With Adverse Events

    Number of participants with treatment-emergent adverse events (TEAEs), grade 3 or higher TEAEs, serious adverse events (SAEs), treatment-related adverse events (AEs), adverse events of special interest, and TEAEs leading to study drug discontinuation, dose reduction and treatment interruption

    Time frame: Up to approximately 3 years and 5 months

07

Results

Posted Mar 8, 2022

Participant flow

This study enrolled participants at 10 study centers in China. The first participant was dosed on 31 August 2017, and the last participant enrolled and received their first dose of zanubrutinib on 08 May 2018. A total of 44 participants were enrolled and all received at least 1 dose of the study drug.

Participant flow — Overall Study
MilestoneZanubrutinib
Started44
Completed0
Not completed44
Withdrew: Death7
Withdrew: Withdrawal by subject6
Withdrew: Lost to follow-up2
Withdrew: Transferred to long-term extension study29

Outcome measures

PrimaryMajor Response Rate (MRR) as Assessed by the Independent Review Committee

MRR is defined as the percentage of participants who achieved complete response (CR) + very good partial response (VGPR) + partial response (PR), as assessed by an independent review committee according to modified Owen's criteria

Time frame:
Up to approximately 1 year and 9 months
Reported as:
Number · Percentage of participants
Major Response Rate (MRR) as Assessed by the Independent Review Committee
Percentage of participantsZanubrutinib
Major Response Rate (MRR) as Assessed by the Independent Review Committee69.8 (53.87 to 82.82)
Statistical analysis
  • Zanubrutinib · Exact binomial test · p = <0.0001 (P value was based on the exact binomial test against the null hypothesis H0: MRR = 0.30 at a significance level of 0.025 (1-sided))
SecondaryProgression Free Survival (PFS)

PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by an independent review committee using modified Owen's criteria

Time frame:
Up to approximately 1 year and 9 months
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsZanubrutinib
Progression Free Survival (PFS)NA (16.53 to NA)
SecondaryPFS: Event-free Rate

Progression/death event-free rates were estimated by Kaplan-Meier method with 95% confidence intervals (CIs) estimated using Greenwood's formula

Time frame:
Up to approximately 1 year and 9 months
Reported as:
Number · Percentage of participants
PFS: Event-free Rate
Percentage of participantsZanubrutinib
6 months89.8 (75.1 to 96.1)
9 months87.0 (71.5 to 94.4)
12 months77.8 (60.2 to 88.3)
SecondaryOverall Response Rate (ORR)

ORR is defined as the percentage of participants with a minor, partial, very good partial, and complete response, as assessed by an independent review committee using modified Owen's criteria

Time frame:
Up to approximately 1 year and 9 months
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR)
Percentage of participantsZanubrutinib
Overall Response Rate (ORR)79.1 (63.96 to 89.96)
SecondaryDuration of Major Response (DOMR)

DOMR is defined as the time from the date that the major response criteria are first met to the date that progressive disease (PD) is objectively documented or death, whichever comes first, as assessed by an independent review committee using modified Owen's criteria

Time frame:
Up to approximately 1 year and 9 months
Reported as:
Median · Months
Duration of Major Response (DOMR)
MonthsZanubrutinib
Duration of Major Response (DOMR)NA (13.77 to NA)
SecondaryDOMR: Event-free Rate

DOMR event-free rates were estimated by Kaplan-Meier method with 95% CIs estimated using Greenwood's formula

Time frame:
Up to approximately 1 year and 9 months
Reported as:
Number · Percentage of participants
DOMR: Event-free Rate
Percentage of participantsZanubrutinib
6 months96.2 (75.7 to 99.4)
9 months87.0 (64.7 to 95.6)
12 months87.0 (64.7 to 95.6)
SecondaryNumber of Participants With Resolution of Treatment-precipitating Symptoms

Number of participants with resolution of treatment-precipitating symptoms, defined as any resolution (from "Yes" at baseline to "No" at any postbaseline point onwards during study) of the indications for initiation of therapy in WM signs and symptoms evaluation.

Time frame:
Up to approximately 1 year and 9 months
Reported as:
Count of participants · Participants
Number of Participants With Resolution of Treatment-precipitating Symptoms
ParticipantsZanubrutinib
Number of Participants With Resolution of Treatment-precipitating Symptoms35
SecondaryNumber of Participants With an Anti-lymphoma Effect

Number of participants with an anti-lymphoma effect, defined as any reduction during the course of study in bone marrow involvement by lymphoplasmacytoid lymphocytes and/or size of lymphadenopathy and/or splenomegaly by computed tomography scan as assessed by an independent review committee; lymphadenopathy is defined as any node with longest diameter (LDi) \> 1.5 cm and splenomegaly is defined as vertical spleen length \> 13 cm

Time frame:
Up to approximately 1 year and 9 months
Reported as:
Count of participants · Participants
Number of Participants With an Anti-lymphoma Effect
ParticipantsZanubrutinib
Number of Participants With an Anti-lymphoma Effect34
SecondaryNumber of Participants With Adverse Events

Number of participants with treatment-emergent adverse events (TEAEs), grade 3 or higher TEAEs, serious adverse events (SAEs), treatment-related adverse events (AEs), adverse events of special interest, and TEAEs leading to study drug discontinuation, dose reduction and treatment interruption

Time frame:
Up to approximately 3 years and 5 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsZanubrutinib
At least one TEAE44
Grade 3 or higher TEAEs34
Serious TEAEs25
Treatment-related TEAEs41
TEAEs of special interest43
TEAEs leading to study drug discontinuation5
TEAEs leading to treatment interruption17
TEAEs leading to dose reduction1

Adverse events

Collected over Up to approximately 3 years and 5 months. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zanubrutinib7/44 (15.9%)25/44 (56.8%)44/44 (100%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventZanubrutinib
PneumoniaInfections and infestations10/44
Upper respiratory tract infectionInfections and infestations3/44
Skin infectionInfections and infestations2/44
Pleural effusionRespiratory, thoracic and mediastinal disorders2/44
AnaemiaBlood and lymphatic system disorders1/44
Arteriosclerosis coronary arteryCardiac disorders1/44
Coronary artery diseaseCardiac disorders1/44
CataractEye disorders1/44
Macular degenerationEye disorders1/44
DysbiosisGastrointestinal disorders1/44
Most frequent other events
Showing 10 of 79
Most frequent other events
EventZanubrutinib
Neutrophil count decreasedInvestigations26/44
White blood cell count decreasedInvestigations14/44
Platelet count decreasedInvestigations13/44
Upper respiratory tract infectionInfections and infestations12/44
DiarrhoeaGastrointestinal disorders11/44
Weight increasedInvestigations10/44
PneumoniaInfections and infestations9/44
ArthralgiaMusculoskeletal and connective tissue disorders9/44
AnaemiaBlood and lymphatic system disorders8/44
Urinary tract infectionInfections and infestations8/44

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Zanubrutinib
Mean64.7 ± 8.10
Sex: Female, Male
Sex: Female, Male(Participants)Zanubrutinib
Female17
Male27
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Zanubrutinib
Chinese44
08

Study locations

10 sites
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing 100021, China
  • Peking Union Medical College Hospital
    Beijing, Beijing 100730, China
  • Guangdong Provincial Peoples Hospital
    Guangzhou, Guangdong 510080, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
  • The First Affiliated Hospital of Soochow University Branch Shizi
    Suzhou, Jiangsu 215006, China
  • Rui Jin Hospital Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai 200025, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310003, China
09

References and documents

Publications

  • An G, Zhou D, Cheng S, Zhou K, Li J, Zhou J, Xie L, Jin J, Zhong L, Yan L, Guo H, Du C, Zhong J, Yu Y, Wu B, Qiu L. A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenstrom Macroglobulinemia. Clin Cancer Res. 2021 Oct 15;27(20):5492-5501. doi: 10.1158/1078-0432.CCR-21-0539. Epub 2021 Jul 12. PubMed 34253577 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in May 2019, 20 months.

Results were first posted in Mar 2022, 2 years 10 months after primary completion.

Of 66 phase 2 interventional studies under Waldenstrom Macroglobulinemia, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 103. This study's 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2017
First posted
Nov 6, 2017
StartActual
Aug 31, 2017
Primary completionActual
May 8, 2019
CompletionActual
Jan 11, 2021
Results first posted
Mar 8, 2022
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03332173
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Nov 6, 2017
Start date
Aug 31, 2017
Primary completion
May 8, 2019
Completion
Jan 11, 2021
Results posted
Mar 8, 2022
Last update
Oct 26, 2024

Study contacts

Study Director
principal investigator · BeiGene

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanubrutinib

Start the discussion